

NEW DRUGS

中国药学会系列期刊/《CAJ-CD》规范执行优秀期刊/美国《化学文摘》荷兰SCOPUS等国际著名检索系统收录  
中国中文核心期刊 中国科技核心期刊 中国科学引文数据库来源期刊

中国新药杂志

二〇二二年

第三十二卷

第十八期

第1761-1864页

半月刊

CHINESE JOURNAL OF NEW DRUGS

ISSN 1003-3734  
CN 11-2850/R  
CODEN ZXZHA6

# 中国新药杂志



18  
2022  
Vol.31 | No.18

持续深化药品审评审批制度改革以优异成绩迎接党的二十大胜利召开  
单克隆抗体药物风险因素分析及非临床研究与评价的一般考虑  
新型冠状病毒肺炎疫情常态化防控期间发热临床试验项目运行面临的问题  
及对策建议  
中药注射剂新药 I 期临床试验中的质量控制  
橙皮苷与陈皮酶转化工艺研究及其对正常小鼠小肠推进作用的比较

www.newdrug.cn

ISSN 1003-3734



国家药品监督管理局主管



## •新药述评与论坛•

- 1761 持续深化药品审评审批制度改革以优异成绩迎接党的二十大胜利召开.....孔繁圃
- 1767 美国“专利舞蹈”制度研究及启示.....王秀, 李佳明, 姚雪芳, 等
- 1774 基于偏最小二乘-二阶因子模型的中药新药综合疗效评价实例研究.....赵阳, 孙明月, 高洪阳, 等
- 1779 治疗进行性家族性肝内胆汁淤积症新药Bylvay.....李妍, 刘晓艳, 何心

## •新药注册与审评技术•

- 1784 单克隆抗体药物风险因素分析及非临床研究与评价的一般考虑.....戴学栋, 王寅, 周恒, 等
- 1793 我国药品注册行政受理的发展历程及实施现状.....董旻, 武志昂, 崔晶
- 1801 应用模拟目标临床试验概念设计观察性研究时的若干考虑.....赵骏, 王骏

## •重大新药创制专项巡礼•

- 1804 新型冠状病毒肺炎疫情常态化防控期间发热临床试验项目运行面临问题及对策建议.....程金莲, 朱雪琦, 刘琳, 等

## •生物医药前沿•

- 1810 携带 $\beta$ -内酰胺酶基因的表达载体在哺乳动物细胞表达系统中应用风险评估.....李靖, 韦苏珍, 贺华, 等

## •综述•

- 1815 罗沙司他治疗肾性贫血的临床应用研究进展.....申芳丽, 宋沧桑, 李兴德, 等

## •I期临床研究规范化进展专栏•

- 1823 中药注射剂新药I期临床试验中的质量控制.....张晶晶, 刘小源, 邱润泽, 等
- 1828 I期临床试验风险防范的清单式管理.....郭伟一, 冯仕银, 蔡林芮, 等

## •实验研究•

- 1831 橙皮苷与陈皮酶转化工艺研究及其对正常小鼠小肠推进作用的比较.....杨元丰, 黎艳刚, 罗小泉, 等
- 1838 复合维生素B注射液致家兔肌肉刺激的研究.....吴彦霖, 耿颖, 张媛, 等
- 1845 响应面法优化医心三黄膏提取工艺及多指标定量指纹图谱研究.....于倩, 陈佳俊, 沈颖昕, 等
- 1853 HPLC-CAD法同时测定聚乙二醇及壬苯醇醚的含量.....张伟, 孙悦, 张慧, 等

## •药物安全与合理应用•

- 1858 我院104例患者多黏菌素B临床应用的回顾性分析.....刘红, 王小华, 邵敏, 等

- 1761 Continue to deepen the reform of drug review and approval system and greet the successful holding of the 20<sup>th</sup> National Congress of CPC with outstanding achievements  
KONG Fan-pu
- 1767 Study on the “patent dance” system in the United States and its implication for China  
WANG Xiu , LI Jia-ming , YAO Xue-fang , *et al*
- 1774 A case study of comprehensive efficacy evaluation of traditional Chinese medicines based on partial least squares second-order latent variable model  
ZHAO Yang , SUN Ming-yue , GAO Hong-yang , *et al*
- 1779 Bylvay, a new drug for the treatment of progressive familial intrahepatic cholestasis  
LI Yan , LIU Xiao-yan , HE Xin
- 1784 Analysis of risk factors of monoclonal antibody drugs and general considerations of non-clinical research and evaluation  
DAI Xue-dong , WANG Yin , ZHOU Heng , *et al*
- 1793 The development history and current implementation status of drug registration administrative acceptance in China  
DONG Min , WU Zhi-ang , CUI Jing
- 1801 Considerations for designing observational studies using targeted trial emulation concept  
ZHAO Jun , WANG Jun
- 1804 Problems faced in the operation of clinical trials for diseases involving fever during the regular COVID-19 prevention and control period and countermeasures  
CHENG Jin-lian , ZHU Xue-qi , LIU Lin , *et al*
- 1810 Risk assessment of  $\beta$ -lactamase gene in mammalian cell expression system  
LI Jing , WEI Su-zhen , HE Hua , *et al*
- 1815 The progresses of clinical trials of roxadustat in the treatment of renal anemia  
SHEN Fang-li , SONG Cang-sang , LI Xing-de , *et al*
- 1823 Quality control in phase I clinical trials of traditional Chinese medicine injections  
ZHANG Jing-jing , LIU Xiao-yuan , QIU Run-ze , *et al*
- 1828 Checklist management of risk prevention in phase I clinical trials  
GUO Wei-yi , FENG Shi-yin , CAI Lin-rui , *et al*
- 1831 Enzymatic transformation of hesperidin and Citri Reticulatae Pericarpium and comparison of their promoting effects on small intestine of normal mice  
YANG Yuan-feng , LI Yan-gang , LUO Xiao-quan , *et al*
- 1838 The stimulation induced by Vitamin B Complex Injection in rabbit muscle irritation test  
WU Yan-lin , GENG Ying , ZHANG Yuan , *et al*
- 1845 Response surface methodology to optimize the extraction process of Yixin Sanhuang Ointment and multiple indexes quantitative fingerprinting research  
YU Qian , CHEN Jia-jun , SHEN Ying-xin , *et al*
- 1853 Simultaneous determination of polyethylene glycol and nonoxinol by HPLC-CAD  
ZHANG Wei , SUN Yue , ZHANG Hui , *et al*
- 1858 Retrospective analysis of clinical application of polymyxins B in 104 patients in our hospital  
LIU Hong , WANG Xiao-hua , SHAO Min , *et al*

**Directed by :** National Medical Products Administration

**Sponsored by :** China Medical Science Press  
China National Pharmaceutical Group Corp.  
Chinese Pharmaceutical Association

**Editor-in-Chief :** SANG Guo-wei

**Board Chairman :** SHI Sheng-yi

**Edited by :** Editorial Board of Chinese Journal of New Drugs

**Published by :** Chinese Journal of New Drugs Co., Ltd.

**Address :** Room 317, No.3 Chengming Building, No.2 Xizhimen South Street, Xicheng District, Beijing 100035, China

**Tel :** (010)52722697 / 52722651 / 52723707

**Website:** <http://www.newdrug.cn>

**E-mail :** [bianjibu@newdrug.cn](mailto:bianjibu@newdrug.cn)

**Printer :** Beijing Kexin Printing Co., Ltd.

**Domestic Distribution :** Beijing Post Offices

**Overseas Distribution :** China International Book Trading Corp.  
(P.O.Box 399 Beijing, China)

**Domestic Subscription :** Local Post Offices

**Periodical Registration :** ISSN 1003-3734 CN 11-2850/R

**Publication Date :** September 30, 2022

**Copyright :** 2022 by Chinese Journal of New Drugs Co.,Ltd.